phase iia - Robuta Search

https://www.news-medical.net/news/20120614/Hay-fever-vaccine-shows-efficacy-in-phase-IIa-trial.aspx Hay fever vaccine shows efficacy in phase IIa trial Jun 18, 2019 - A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative... hay fever in phase vaccine shows efficacy https://www.globenewswire.com/news-release/2025/06/16/3099883/0/en/Can-Fite-to-Present-Phase-IIa-Pancreatic-Cancer-Study-Progress-During-Partnering-Meetings-at-the-2025-BIO-International-Convention-in-Boston.html Can-Fite to Present Phase IIa Pancreatic Cancer Study Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company... phase iia pancreatic cancer fite present study https://www.businesswire.com/news/home/20241105093592/de RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei... RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachst... phase iia https://www.hss.edu/research/clinical-trials/nelfinavir-sle-systemic-lupus-erythematosus Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial systemic lupus erythematosus pilot phase nelfinavir https://www.newswire.com/news/intralytix-receives-fda-clearance-to-initiate-phase-i-iia-clinical-20261300 Intralytix Receives FDA Clearance to Initiate Phase I / IIa Clinical Trials | Newswire https://www.biospace.com/clearmind-medicine-obtains-ind-approval-from-the-fda-to-start-the-phase-i-iia-clinical-trial-with-its-innovative-treatment-for-alcoholism Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with... https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/spago-nanomedicals-phase-i%2Fiia-study-tumorad-01-meets-a-primary-endpo-1164159 Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further... LUND, SE / ACCESS Newswire / May 6, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the independent Data... https://www.biospace.com/kangpu-biopharmaceuticals-initiates-phase-ib-iia-clinical-trial-of-kpg-818-in-systemic-lupus-erythematosus Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus... Nov 17, 2020 - Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China , announced that, after consulting with the U.S. Food and Drug Administration... https://www.biospace.com/immupharma-plc-update-on-progress-of-phase-i-iia-clinical-trial ImmuPharma plc - Update on Progress of Phase I/IIa Clinical Trial - BioSpace on progress https://www.prnewswire.com/il/news-releases/neurosense-announces-peer-reviewed-publication-of-primec-phase-iia-als-study-in-amyotrophic-lateral-sclerosis-and-frontotemporal-degeneration-301627181.html NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral... /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today... https://www.biospace.com/press-releases/spago-nanomedical-continues-patient-recruitment-in-the-phase-i-iia-study-tumorad-01-as-planned-after-dmc-recommendation Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned... https://www.biospace.com/b-wex-b-initiates-phase-iia-clinical-trial-of-tetrodin-tm-for-reduction-of-withdrawal-symptoms-in-opiate-dependent-patients Wex Initiates Phase IIa Clinical Trial Of Tetrodin"TM" For Reduction Of Withdrawal Symptoms In... https://www.prnewswire.com/news-releases/gyala-therapeutics-initiates-phase-iiia-clinical-trial-of-a-car-t-cell-therapy-in-acute-leukemias-with-limited-treatment-options-302681392.html Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias... /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced... https://www.prnewswire.com/news-releases/fda-grants-ind-approval-for-phase-iia-clinical-trial-using-stemedicas-itmsc-therapy-to-treat-alzheimers-disease-300096115.html FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica's itMSC Therapy to Treat... /PRNewswire/ -- Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical... https://www.biospace.com/press-releases/qbiotics-reports-80-objective-response-rate-in-injected-tumours-in-stage-1-of-phase-iia-clinical-trial-of-tigilanol-tiglate-for-soft-tissue-sarcoma QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL... https://www.biospace.com/bone-therapeutics-treats-first-patients-in-allob-phase-iia-spinal-fusion-trial Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial - BioSpace https://www.biospace.com/press-releases/ribox-therapeutics-announces-first-patient-dosed-in-phase-i-iia-clinical-trial-of-rxrg001-the-first-circular-rna-therapy-for-the-treatment-of-radiation-induced-xerostomia-and-hyposalivation RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the... https://www.prnewswire.com/news-releases/intralytix-receives-fda-clearance-to-initiate-phase-i--iia-clinical-trials-300599772.html Intralytix Receives FDA Clearance to Initiate Phase I / IIa Clinical Trials /PRNewswire/ -- Intralytix, Inc. announced today that it received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical... phase i intralytix receives fda clearance https://menafn.com/1110003751/FIRST-PATIENT-DOSED-IN-CITRYLLs-PHASE-IIA-TRIAL-EVALUATING-CIT-013-IN-RHEUMATOID-ARTHRITIS FIRST PATIENT DOSED IN CITRYLL's PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS https://www.prnewswire.com/news-releases/stemedica-cell-technologies-announces-completion-of-enrollment-in-phase-iiia-clinical-trial-for-ischemic-stroke-300210445.html Stemedica Cell Technologies Announces Completion of Enrollment in Phase I/IIa Clinical Trial for... /PRNewswire/ -- Stemedica Cell Technologies, Inc. announced completion of enrollment into "A Phase I/IIa, Multi-Center, Open-Label Study to Assess the... https://www.prnewswire.co.uk/news-releases/betagenonbaltic-bio-announces-positive-results-from-a-28-day-phase-iia-trial-of-the-first-in-class-ampk-654655663.html Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class... /PRNewswire/ -- O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabeticsThe main study results are not yet finalized. Review of the... https://www.prnewswire.com/news-releases/fda-grants-ind-approval-to-stemedica-for-a-traumatic-brain-injury-phase-iia-clinical-trial-300270684.html FDA Grants IND Approval to Stemedica for a Traumatic Brain Injury Phase IIa Clinical Trial /PRNewswire/ -- Stemedica Cell Technologies, Inc. (Stemedica) received an FDA investigational new drug (IND) approval for a United States-based, Phase IIa... https://www.biospace.com/nmd-pharma-to-present-nmd670-clinical-data-from-a-phase-i-iia-trial-in-myasthenia-gravis-at-the-28th-international-annual-congress-of-the-world-muscle-society NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the... Oct 3, 2023 - NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within... https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-iia-study-results-for-a-new-first-in-class-candidate-medicine/ GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for... Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future. https://www.biospace.com/biontech-and-genmab-initiate-first-in-human-phase-i-iia-trial-of-bispecific-antibody-duobody-pd-l1x4-1bb-in-solid-tumors BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody... Jun 17, 2019 - BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases,... https://www.businesswire.com/news/home/20251218979803/en/Qihan-Biotech-Initiates-Dosing-in-Phase-IIIa-Clinical-Trial-with-Off-the-Shelf-Allogeneic-CAR-T-Therapy-for-Refractory-Systemic-Lupus-Erythematosus Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T... Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-T ... https://www.businesswire.com/news/home/20260421709537/en/Tubulis-to-Present-Phase-IIIa-Trial-Data-for-ADC-Candidate-TUB-040-in-Platinum-resistant-Ovarian-Cancer-in-Rapid-Oral-Presentation-at-ASCO-2026 Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian... Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepte... https://www.ncdot.gov/projects/us-64-phase-ii/Pages/default.aspx NCDOT: Strategic Highway Corridors, U.S. 64 Corridor Study - Phase IIA u s 64 ncdot strategic highway corridors https://kffhealthnews.org/morning-breakout/dr00032199/ Phase IIa Trial of Panacos Antiretroviral Shows Up To 90% Reduction in HIV Viral Load - KFF Health... Phase IIa Trial of Panacos Antiretroviral Shows Up To 90% Reduction in HIV Viral Load https://www.biospace.com/pipex-pharmaceuticals-oral-trimesta-phase-iia-clinical-and-preclinical-findings-presented-at-world-congress-on-treatment-and-research-in-multiple-scl Pipex Pharmaceuticals' Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World... https://www.news-medical.net/news/20100407/Updates-from-Phase-IIIa-clinical-trial-of-DIABECELL-treatment-in-insulin-dependent-diabetics.aspx Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics Jun 17, 2019 - Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update... https://www.nsf.gov/funding/opportunities/dcl-supplemental-opportunity-sbirsttr-cresthbcu-rise/nsf10-055 Supplemental Opportunity for SBIR/STTR for CREST/HBCU-RISE Collaborations - Phase IIA | NSF - U.S.... https://www.southampton.ac.uk/research/projects/g-griffiths-agile-seamless-phase-iiia-platform-for-the-rapid-evaluation-of G. Griffiths. AGILE: Seamless Phase I/Iia Platform for the Rapid Evaluation of Candidates for... G. Griffiths. AGILE: Seamless Phase I/Iia Platform for the Rapid Evaluation of Candidates for COVID-19 treatment. https://www.businesswire.com/news/home/20240109780600/en/European-Medicines-Agency-EMA-Greenlights-Mitochon-Pharmaceuticals-to-Initiate-Phase-IIIa-Biomarker-Study-in-Neurodegenerative-Diseases European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I/IIa... Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral S... european medicines agency https://www.biospace.com/oryzon-announces-journal-publication-of-final-phase-iia-alice-results-with-iadademstat-in-the-lancet-hematology ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The... Jul 17, 2024 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination... https://www.prnewswire.com/news-releases/earendil-labs-announces-first-patient-dosed-in-a-phase-iia-trial-of-a-half-life-extended-anti-tl1a-antibody-hxn-1001-in-patients-with-ulcerative-colitis-302732675.html Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A... /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a...